BNP (B-type Natriuretic Peptide) vs MK-677 (Ibutamoren)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →MK-677 (Ibutamoren)
MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | MK-677 (Ibutamoren) |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 10 mg–25 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 8–24 weeks |
| Route | subcutaneous | oral |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Acts as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Typical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Oral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Increased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), MK-677 (Ibutamoren) are both commonly used for:
Key Differences
Unique to MK-677 (Ibutamoren):
Which Has Stronger Evidence?
| Goal | BNP (B-type Natriuretic Peptide) | MK-677 (Ibutamoren) |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
MK-677 (Ibutamoren)
- Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.
Clinica chimica acta; international journal of clinical chemistry, 2026
- Hepatotoxicity induced by MK-677.
BMJ case reports, 2025
- Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
Basic & clinical pharmacology & toxicology, 2025
Ready to Learn More?
Looking for trusted sources?